Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 484
- Registration Number
- NCT06475729
- Locations
- 🇺🇸
CenExel ACT, Anaheim, California, United States
🇺🇸Fortrea Clinical Research Unit, Madison, Wisconsin, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Conditions
- Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid TumorUrinary Bladder NeoplasmTriple Negative Breast CancerNon-small Cell Lung CancerEsophageal CancerPancreatic CancerOvarian CancerCervical Cancer
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 420
- Registration Number
- NCT06465069
- Locations
- 🇪🇸
Hospital Madrid Norte Sanchinarro, Madrid, Spain
🇪🇸Hospital Universitario Virgen Del Rocio, Sevilla, Spain
🇬🇧St Bartholomew's Hospital, London, United Kingdom
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 55
- Registration Number
- NCT06444165
- Locations
- 🇺🇸
Concentrics Research, Indianapolis, Indiana, United States
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 508
- Registration Number
- NCT06440980
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States
🇺🇸Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT06439277
- Locations
- 🇦🇷
Fundación Respirar, Buenos Aires, Argentina
🇲🇽Consultorio Médico de Endocrinología y Pediatría, Puebla, Mexico
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT06413706
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Rhode Island Hospital/Hasbro Children's Hospital, Providence, Rhode Island, United States
🇺🇸UT Health San Antonio, San Antonio, Texas, United States
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- Conditions
- Ovarian NeoplasmsEndometrial NeoplasmsColorectal NeoplasmsUterine Cervical NeoplasmsPancreatic NeoplasmCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT06400472
- Locations
- 🇪🇸
Hospital Clinico Universitario de Valencia, Valencia, Spain
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), Grand Rapids, Michigan, United States
A First-In-Human Study of LY3985297 in Healthy Participants
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 153
- Registration Number
- NCT06395012
- Locations
- 🇺🇸
CenExel ACT, Anaheim, California, United States
🇺🇸ICON, Salt Lake City, Utah, United States
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD)Chronic Kidney Disease (CKD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10000
- Registration Number
- NCT06383390
- Locations
- 🇺🇸
Alabama Kidney Research, Alabaster, Alabama, United States
🇺🇸Central Research Associates, Birmingham, Alabama, United States
🇺🇸Alliance for Multispecialty Research, LLC, Norfolk, Virginia, United States
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT06373146
- Locations
- 🇺🇸
Velocity Clinical Research, Gardena, Gardena, California, United States
🇺🇸Irvine Clinical Research, Irvine, California, United States
🇺🇸Velocity Clinical Research, Westlake, Los Angeles, California, United States